Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804268 | 0.96 | HPGD (0.57) | ALDH1A1L3MBTL1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL4001868 | 0.89 | ALDH1A1 (0.74) | ALDH1A1L3MBTL1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL4001869 | 0.89 | ALDH1A1 (0.74) | ALDH1A1L3MBTL1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL27011217 | 0.89 | ALDH1A1 (0.74) | ALDH1A1L3MBTL1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL18767537 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL27011294 | 0.85 | ROCK2 (0.59) | ALDH1A1L3MBTL1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL27011332 | 0.85 | ROCK2 (0.59) | ALDH1A1L3MBTL1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL15743801 | 0.84 | HCRTR1 (0.53) | ALDH1A1L3MBTL1 | |
| SCHEMBL5540004 | 0.84 | ALDH1A1 (0.67) | ALDH1A1L3MBTL1HPGDNPSR1GAA | |
| SCHEMBL13753517 | 0.82 | HPGD (0.71) | ALDH1A1HPGDSMN1; SMN2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmaceuticals (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | FLI1, MCL1, SP1 | ALDH1A1 312/4885L3MBTL1 1057/4885HPGD 1835/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | ALDH1A1 2667/4885L3MBTL1 2718/4885HPGD 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.